Cel-Sci Corp (CVM) Stock Price, Quote & News

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 506 9460

Website: cel-sci.com

Address:

8229 Boone Boulevard, Suite 802, Vienna, United States

ImmxBeliever Feb. 12 at 7:56 PM

$CVM

0 · Reply

ImmxBeliever Feb. 12 at 7:16 PM

$CVM

0 · Reply

Ichigodoran Feb. 12 at 7:14 PM

$CVM $WTER $VRME #MWAI loading

0 · Reply

Easygoer712 Feb. 12 at 3:15 PM

$CVM Saudi SFDA closed for the weekend. See you all next week ...... news on Sunday ????

3 · Reply

vivy123 Feb. 12 at 2:12 PM

$CVM Saudi Arabia SFDA~ Are you still crying about it? 😂😂😂 A year ago, you were shouting about “summer commercialization” and “60-day approval.” How did that turn out? Every single thing was wrong. If I were the CEO, I’d delay the SFDA result for 10 years. That’s 10 years of legally doing equity offerings, right? And you guys? You’ll keep yelling “Saudi Arabia! SFDA!!!” while handing more money to the company 😂

0 · Reply

vivy123 Feb. 12 at 2:12 PM

0 · Reply

vivy123 Feb. 12 at 2:11 PM

0 · Reply

prophet777 Feb. 12 at 2:02 PM

$CVM Geert correction we will reach 2 sooner than 10 days it looks like by Friday or Monday. So you can “dilute” your investors at 1 per some woke lady here… we know we know you don’t care…

0 · Reply

GuruChartist Feb. 11 at 10:17 PM

$CVM Neck and throat cancer is a horrible diagnosis. If the Standard of Care (SOC) for these cancers could change using the immune system, it would shift the prgnosis for these patients dramatically. $GOVX is another biotech doing work on these cancers too.

1 · Reply

SmallCapGrowth Feb. 11 at 6:17 PM

$CVM Cel-Sci #NYSE Big research - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6815250

0 · Reply

CEL-SCI Reports Fiscal 2025 Results

Oct 20, 2025, 9:00 AM EDT - 4 months ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 10, 2025, 8:00 AM EDT - 4 months ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Aug 29, 2025, 12:52 PM EDT - 5 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 6 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 5:25 PM EDT - 6 months ago

CEL-SCI Announces Proposed Public Offering

Aug 14, 2025, 10:45 AM EDT - 6 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 13, 2025, 9:15 AM EDT - 6 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Jul 14, 2025, 4:05 PM EDT - 7 months ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 7 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 9:15 AM EDT - 7 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jun 18, 2025, 9:00 AM EDT - 8 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

May 23, 2025, 4:05 PM EDT - 9 months ago

CEL-SCI Announces Closing of Public Offering

May 21, 2025, 8:14 PM EDT - 9 months ago

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:00 AM EDT - 9 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 19, 2025, 2:40 PM EDT - 9 months ago

CEL-SCI Announces Combination of Common Stock

May 15, 2025, 9:00 AM EDT - 9 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

Apr 23, 2025, 8:30 AM EDT - 10 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 8, 2025, 9:51 AM EDT - 11 months ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Mar 24, 2025, 9:00 AM EDT - 11 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 18, 2025, 4:05 PM EDT - 11 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 11 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 8:00 AM EDT - 11 months ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 14, 2025, 8:30 AM EDT - 11 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Feb 20, 2025, 8:00 AM EST - 1 year ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 18, 2025, 8:30 AM EST - 1 year ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Jan 14, 2025, 9:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Nov 8, 2024, 8:00 AM EST - 1 year ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

May 16, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 8, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Mar 19, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

ImmxBeliever Feb. 12 at 7:56 PM

$CVM

0 · Reply

ImmxBeliever Feb. 12 at 7:16 PM

$CVM

0 · Reply

Ichigodoran Feb. 12 at 7:14 PM

$CVM $WTER $VRME #MWAI loading

0 · Reply

Easygoer712 Feb. 12 at 3:15 PM

$CVM Saudi SFDA closed for the weekend. See you all next week ...... news on Sunday ????

3 · Reply

vivy123 Feb. 12 at 2:12 PM

0 · Reply

vivy123 Feb. 12 at 2:12 PM

0 · Reply

vivy123 Feb. 12 at 2:11 PM

0 · Reply

prophet777 Feb. 12 at 2:02 PM

$CVM Geert correction we will reach 2 sooner than 10 days it looks like by Friday or Monday. So you can “dilute” your investors at 1 per some woke lady here… we know we know you don’t care…

0 · Reply

GuruChartist Feb. 11 at 10:17 PM

1 · Reply

SmallCapGrowth Feb. 11 at 6:17 PM

$CVM Cel-Sci #NYSE Big research - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6815250

0 · Reply

ImmxBeliever Feb. 11 at 4:49 PM

$CVM “delute”

1 · Reply

prophet777 Feb. 11 at 4:22 PM

$CVM I wonder per some lady here at what price will the genius Geert delute his investors… if it goes down .2-.3 a day in 10 days it will be at 1-2. I mean he used to fuck his investors at .2 so…

0 · Reply

SmallCapGrowth Feb. 11 at 4:18 PM

BB's Stock Haven : $CVM Cel-Sci #NYSE Big research report j... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177285948 via @Investors_Hub

1 · Reply

Cruiser24 Feb. 11 at 4:10 PM

$CVM BULLISH How much fuel is in tank? Perhaps the next earnings report will tell? When is the next earnings report? : The next earnings report for CEL-SCI Corporation (CVM), covering fiscal Q1 2026 (quarter ended December 31, 2025), has not been officially announced by the company as of February 11, 2026. However, based on historical patterns and analyst estimates, it is projected for mid-February 2026. Specific estimates include: • February 12, 2026 (Yahoo Finance) • February 13, 2026 (Nasdaq, GuruFocus, http://StockInvest.us) • February 15, 2026 (TipRanks, MarketScreener) As a non-accelerated filer, the regulatory due date for the 10-Q filing is February 14, 2026 (45 days after quarter end). The company typically reports around this timeframe, often with a conference call. Monitor the company’s press releases or SEC filings for the confirmed date. GOOD LUCK BULLS 💎✋🤚💎 💎✋🤚💎

1 · Reply

Cruiser24 Feb. 11 at 3:09 PM

$CVM BULLISH Day 182.How much closer can we get without the decision being made? GOOD LUCK BULLS 💎✋🤚💎 💎✋🤚💎

0 · Reply

ImmxBeliever Feb. 11 at 3:05 PM

$CVM Or one day closer to rejection Both can be true

1 · Reply

SmallCapGrowth Feb. 11 at 1:27 PM

$CVM Cel-Sci #NYSE Big research report just released by #ThinkEquity Awesome let’s sum it up for you! https://www.youtube.com/watch?v=AEGLwVGkn-c #CVM #STOCKSTOWATCH #TheBullRunShow #STOCKS @TheBullRunShow

1 · Reply